Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 20, 2020 - Issue 6
Submit an article Journal homepage
725
Views
10
CrossRef citations to date
0
Altmetric
Review

Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease

Anders Gustavssona Quantify Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, SwedenView further author information
,
Peter Pemberton-Rossb Value & Access, Biogen International GmbH, Baar, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6739-1873View further author information
ORCID Icon,
Melissa Gomez Monteroc Ingress-Health, Rotterdam, The NetherlandsView further author information
,
Mahmoud Hashimc Ingress-Health, Rotterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-5775-9590View further author information
ORCID Icon &
Robin Thompsonb Value & Access, Biogen International GmbH, Baar, SwitzerlandView further author information
Pages 563-570 | Received 21 Aug 2020, Accepted 09 Sep 2020, Published online: 20 Sep 2020

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anders Wimo. (2021) What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 1-4.
Read now
Charles Makin, Peter Neumann, Sue Peschin & Dana Goldman. (2021) Modelling the value of innovative treatments for Alzheimer’s disease in the United States. Journal of Medical Economics 24:1, pages 764-769.
Read now

Articles from other publishers (8)

Ron L.H. Handels, Colin Green, Anders Gustavsson, William L. Herring, Bengt Winblad, Anders Wimo, Anders Sköldunger, Andreas Karlsson, Robert Anderson, Mark Belger, Chiara Brück, Robert Espinosa, Jakub P. Hlávka, Eric Jutkowitz, Pei‐Jung Lin, Mauricio Lopez Mendez, Javier Mar, Peter Shewmaker, Eldon Spackman, Ali Tafazzoli, Bryan Tysinger & Linus Jönsson. (2022) Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge. Alzheimer's & Dementia 19:5, pages 1800-1820.
Crossref
Manisha Thakkur, Hagera Dilnashin & Priyanka Kumari Keshri. 2023. Traditional Medicine for Neuronal Health. Traditional Medicine for Neuronal Health 265 283 .
Arenda Mank, Judith J. M. Rijnhart, Ingrid S. van Maurik, Linus Jönsson, Ron Handels, Els D. Bakker, Charlotte E. Teunissen, Bart N. M. van Berckel, Argonde C. van Harten, Johannes Berkhof & Wiesje M. van der Flier. (2022) A longitudinal study on quality of life along the spectrum of Alzheimer’s disease. Alzheimer's Research & Therapy 14:1.
Crossref
A.N. Bogolepova, E.V. Brovko, S.I. Gavrilova, M.V. Gantman, R.O. Dreval, S.N. Illarioshkin, E.A. Katunina, C. Konson, G.P. Kostjuk, J.V. Kotovskaja, O.S. Levin, I.V. Litvinenko, V.E. Medvedev, E.A. Mkhitarjan, N.G. Neznanov, E.J. Onegina, V.A. Parfenov, O.N. Tkacheva, E.J. Fedotova, A.L. Shchetkina & N.N. Yakhno. (2022) Roadmap for ecosystem-based approach for patients with Alzheimer disease in Russia: current needs, barriers, and possible solutions (resolution of the scientific and practical experts meeting). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:7, pages 121.
Crossref
Filipa Landeiro, Jasmine Morton, Anders Gustavsson, Michele Potashman, Pascal Lecomte, Mark Belger, Robin Thompson, Emilse Roncancio‐Diaz, Gurleen Jhuti, Christopher Butler, Linus Jönsson, Ron Handels & Alastair M. Gray. (2022) Health economic modeling for Alzheimer's disease: Expert perspectives. Alzheimer's & Dementia: Translational Research & Clinical Interventions 8:1.
Crossref
Maria J. Prados, Ying Liu, Hankyung Jun, Jenny Lam & Soeren Mattke. (2022) Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States. Alzheimer's & Dementia 18:1, pages 142-151.
Crossref
William L. Herring, Ian Gopal Gould, Howard Fillit, Peter Lindgren, Fiona Forrestal, Robin Thompson & Peter Pemberton-Ross. (2021) Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease. Neurology and Therapy 10:2, pages 919-940.
Crossref
Anders Gustavsson, Lars Lau Raket, Mathias Lilja, Loes Rutten‐Jacobs, Hanna Fues Wahl, Marloes Bagijn, Erik Stomrud, Oskar Hansson & Sebastian Palmqvist. (2021) Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease‐modifying treatments—EQ‐5D data from the Swedish BioFINDER study. Alzheimer's & Dementia 17:11, pages 1832-1842.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.